Abstract
Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Central Nervous System Agents in Medicinal Chemistry
Title: Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients
Volume: 7 Issue: 3
Author(s): Yuji Odagaki
Affiliation:
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Abstract: Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Export Options
About this article
Cite this article as:
Odagaki Yuji, Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152407781669125
DOI https://dx.doi.org/10.2174/187152407781669125 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold
Current Neuropharmacology Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Partial Dopamine Agonists and the Treatment of Psychosis
Current Neuropharmacology Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology